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Chronic urticaria (CU) defined as repeatedly occurred itchy wheals and/or  
angioedema for at least 6 weeks. Due to the unpredictability, recurrent and dis-
abling symptoms, and a considerably impaired quality of life, effective and tolerable 
treatment for CU patients is crucial. Almost a half of patients with CU are refrac-
tory to H1-antihistamines, even though the dose of antihistamines is increased 
up to 4-fold. Recently treatment modulating IgE levels and activities provides an 
efficient therapeutic approach. Omalizumab, the only approved anti-IgE treatment 
for chronic spontaneous urticaria (CSU) patients until now, with a strong evidence 
of the efficacy and safety, opened a new horizon in the care of the patients whose 
urticaria is not controlled with antihistamines. Recent international guidelines rec-
ommend omalizumab as the first choice of treatment for antihistamine-refractory 
CSU. However, as it is not curative neither disease-modifying agent, there is a sub-
population of CSU patients responding partly or never to omalizumab. The other 
things to be solved in the treatment of CU is that clinical evidence is still limited on 
chronic inducible urticaria (CIndU) and special populations. Thus, a new anti-IgE 
treatment, ligelizumab is actively evaluated in the efficacy compared with both 
placebo and omalizumab. Further understandings on the pathogenesis of CU can 
lead to the development of new mechanism-based therapeutics for CU patients.
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1. Introduction
Symptomatic management to relieve itchy wheals has been recognized as the 
standard of care for chronic urticaria. However, around a half of patients with CU 
are refractory to recommended doses neither an increased doses of antihistamine. 
In these patients whose urticaria are not controlled with non-sedative antihista-
mines, more significantly impaired quality of life has been observed. Management 
guidelines for CU in past included omalizumab, cyclosporine, dapsone, hydroxy-
chloroquine, methotrexate, montelukast, colchine, and phototherapy as alternative 
treatment for antihistamine-refractory CU [1, 2]. However, most of recent guide-
lines recommend omalizumab for the first of choice among various immunomodu-
lating agents based on lots of study results [3, 4].
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Omalizumab is the only biologics, approved for management of chronic 
spontaneous urticaria (CSU) in patients at age 12 years or older by Food and Drug 
Administration (FDA). It a recombinant humanized IgG1, monoclonal anti-IgE 
antibody. Although the pathophysiology of CU is not completely established, it is 
clear that mast cell activation is the key feature of CU. Omalizumab binds to free 
IgE at the Fc region and prohibits IgE from interacting with high-affinity recep-
tor for Fc region of IgE (FcɛRI) on mast cells, basophils and eosinophils [5, 6]. It 
has been shown to downregulate the expression of FcɛRI on both mast cells and 
basophils [7]. This chapter reviews the current evidence of the efficacy, safety, and 
treatment response to biologics targeting IgE, including omalizumab, ligelizumab 
and quilizumab in CU patients.
2. Pivotal phase III trials with omalizumab in patients with CSU
The first successful use of omalizumab for CU was reported by Boyce in 2006 
[8]. The 3 essential phase III multicenter, randomized, double-blinded studies 
that led to the FDA indication for CSU were the ASTERIA I [9] and II [10], and 
GLACIAL [11] trials. These trials included a total of 733 patients on omalizumab 75, 
150, or 300 mg at 4-week intervals and 242 patients were allocated in the placebo 
groups. Clinical efficacy of omalizumab in randomized controlled trials including 
these 3 pivotal trials are summarized in Table 1.
ASTERIA I was a 40-week trial included patients receiving either omalizumab 
75 mg, omalizumab 150 mg, omalizumab 300 mg, or placebo given in 4-week 
intervals for a 24-week treatment period with 16 weeks of follow-up [9]. The 
patients who had failed H1 antihistamine treatment at licenced doses were enrolled. 
All 3 doses of omalizumab met their primary efficacy endpoint of a reduction in 
weekly itch severity score (ISS) at 12 weeks compared with baseline (−6.46 with 
omalizumab 75 mg, −6.66 with omalizumab 150 mg, and − 9.40 with omalizumab 
300 mg). The omalizumab 300 mg group achieved the minimally important dif-
ference in weekly ISS at a significantly shorter duration compared with the other 
omalizumab doses. However, urticaria symptoms returned to placebo levels after 
omalizumab was discontinued in all treatment groups during the follow-up period.
ASTERIA II was a 28-week trial that included 12 weeks of therapy with either 
omalizumab 75 mg, 150 mg, or 300 mg, or placebo in 4-week intervals with a 
16-week follow-up period [10]. The patients having already failed treatment with 
approved doses of H1 antihistamines were included. The group of omalizumab 
75 mg was failed to show significant difference in weekly ISS at 12 weeks compared 
with the placebo group. The omalizumab 150 mg and 300 mg groups reached sig-
nificance for their primary end point of a mean change from baseline in weekly ISS 
at 12 weeks (−8.1 with omalizumab 150 mg and − 9.8 with omalizumab 300 mg), 
as compared with placebo. The proportion of patients who had complete symptom 
control was 16%, 22%, 44%, and 5% for omalizumab 75 mg, 150 mg, 300 mg, and 
placebo groups, respectively. During the 16-week follow-up period, the ISS for all 
omalizumab doses increased to levels similar to those of the placebo group.
GLACIAL trial included patients who had failed H1 antihistamines at up to 4 
times the approved doses in addition to approved doses of leukotriene receptor 
antagonists or H2 antihistamines [11]. These patients were given either omalizumab 
300 mg or placebo every 4 weeks for 24 weeks followed by a 16-week observa-
tion period. The weekly ISS at week 12 compared with baseline was significantly 
improved in the omalizumab 300 mg group compared with placebo (−8.6 with 
omalizumab 300 mg). All the other secondary efficacy end points also met 
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significance for the omalizumab group including change in weekly urticaria activity 
score (UAS7), Dermatology Life Qualirty Index, and proportion of patients who 
were itch and hive free. As with both ASTERIA trials, the effects of omalizumab 
appeared not to be permanent, and weekly ISS increased to placebo levels after 
discontinuing omalizumab treatment.
Recently, several systematic analyses based on various randomized controlled 
trials [9–19] to evaluate the effects of omalizumab for patients with CSU have 
been reported [3, 20–22]. These systematic reviews have provided high-quality 
of evidence on that omalizumab is effective in the treatment of antihistamine-
refractory CSU independent of monthly dose [3, 22]. The dosage of 300 mg every 
4 weeks is found to achieve better results in reductions of disease activity scores and 
in improvement of disease-specific quality of life. However, a recent meta-analysis 
analyzed minimal important differences in urticaria outcome measures, such as 
UAS7, ISS7, and quality of life demonstrated that omalizumab 300 mg resulted 
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NA 36.8% at 12 W
52.0% at 24 W
Table 1. 
Clinical efficacy of omalizumab in randomized controlled trials.
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omalizumab 150 mg failed to prove clinically meaningful improvement in any of 
them as compared with standard of care [20].
3. Optimal dosing and interval of omalizumab treatment
In patients with allergic asthma, optimal dose of omalizumab is determined 
by serum total IgE levels and body weight of the patients. Unlike for allergic 
asthma, the FDA approved omalizumab for the management of CSU at doses 
independent of serum IgE levels or body weight. Based on the 3 pivotal trials, 
[9–11] the approved doses of omalizumab is 150 mg or 300 mg every 4 weeks. 
Doses lower than 150 mg did not consistently show a significant improvement 
in efficacy compared with placebo, and the higher dose of 300 mg dependably 
showed faster and more robust efficacy. Interestingly, higher doses of omali-
zumab at 600 mg were explored in the dose-ranging single omalizumab dose 
phase II MYSTIQUE trial [23, 24]. Although no significant difference in changes 
of UAS7 at week 4 from baseline between the omalizumab 600 mg and 300 mg 
groups, there was also no increase in adverse events [25–27]. Cases of patients 
requiring higher than approved doses, up to 600 mg, to reach complete remission 
have been reported [25, 27].
4. Proper duration of omalizumab treatment
As shown in all phase III trials, cessation of omalizumab resulted in an increase 
in weekly itch and wheal scores and returning to placebo levels within 16 weeks 
[9–11]. These results indicate that omalizumab is effective in controlling symp-
toms, but they do not provide evidence that omalizumab induces remission from 
CSU. Therefore, longer durations of treatment may be required for some patients. 
Omalizumab shows very good safety efficacious at therapeutic durations of more 
than 1 year [23, 24]. As soon as patients achieved complete control, antihistamines 
can be tapered off [4].
Several strategies have been proposed for weaning including reduction monthly 
doses or lengthening the time between doses [28]. A patient-tailored tapering 
protocol on the basis of a patient’s UAS7 scores while on omalizumab treatment is 
needed. Increase the injection interval by 1-week intervals can be recommended 
when the patient achieved a complete response to omalizumab after 6 months of 
treatment [29]. If a patient can tolerate every 8-week injections over a 4-month 
period without increased activity, these patients can often have omalizumab discon-
tinued. Fortunately, most of patients who have experienced relapsed urticaria after 
stopping omalizumab treatment, respond well to retreatment of omalizumab with 
previously effective dose and interval [30, 31].
5. Predictors of the response to omalizumab treatment
In patients with CU, omalizumab is not a disease-modifying or curative treat-
ment. The treatment response to omalizumab in patients with CU is classified 
according to the onset and extent of the response. Fast or early response is defined 
when the onset of therapeutic response to omalizumab in CU patients starts within 
the first 4 weeks. On the other hand, the response appearing gradually by weeks 
12–16 weeks is defined as slow or late response. The extent of therapeutic response 
to omalizumab is based on the UAS7. Complete response includes the patients 
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who achieve UAS7 = 0, no itch and wheal or UAS7 ≤ 6, well-controlled urticaria or 
have a significant improvement in UAS7 reduction from baseline (> 90%). Partial 
response is defined as UAS7 reduction between 30% and 90%. No response means 
that UAS7 reduction is less than 30% from baseline or the exacerbation of itchy 
wheals during omalizumab treatment [32, 33].
Around 70% of patients with CSU who benefit from omalizumab respond 
within the first week of treatment. From the results of 3 pivotal phase III trials, at 
week 4, well-controlled urticaria (UAS7 ≤ 6) was reported by 2 ~ 5%, 12 ~ 15%, 
21 ~ 28%, and 37 ~ 51% of patients receiving placebo, 75, 150, 300 mg of omali-
zumab, respectively. And early response is linked to type I autoimmunity or IgE 
autoantibodies, such as IgE to thyroid persoxidase [13]. The proportion of well-
controlled urticaria and complete responders during the 12-week of active treat-
ment increased continuously. With continuous dosing of omalizumab 300 mg from 
12 weeks to 24 weeks in ASTERIA I [9] and GLACIAL, [11] around a half of patients 
who did not respond at week 12 achieved complete response at week 24. The median 
time to complete response was also dependent on the dose of omalizumab. It was 
noted between 8 and 10 weeks for 300 mg of omalizumab, whereas fewer than 
50% of patients in the 75 mg or 150 mg of omalizumab groups achieved complete 
response within the 12-week of treatment. However, around 40 ~ 50% of patients 
had partly or uncontrolled urticaria even with an active treatment of omalizumab 
for 24 weeks. Thus, before determining non-responders to omalizumab treat-
ment and considering other therapeutics, use of omalizumab for at least 6 months 
is needed.
There are no markers to predict when their CSU will go into remission. Despite 
older and higher disease activity at onset, being female, and hypersensitivity to 
nonsteroidal anti-inflammatory drugs, comorbid CIndU, presence of angioedema, 
and thyroid disease were all reported to be associated with longer urticaria duration 
in CSU patients, [29] however, none on these markers guides to decide when to 
discontinue omalizumab.
Lower levels of serum total IgE at baseline (< 40 IU/mL) and decreased ratio of 
IgE levels at 4 weeks by baseline levels (<2.0) have been associated with higher risk 
of non-responder to omalizumab treatment in CSU patients [34]. Positive response 
to diagnostic tests for type IIb autoimmunity including basophil histamine releas-
ibility assay, autologous serum skin test, and anti-FcεRI autoantibody in the sera 
from CSU patients are regarded as indicators for slow or poor response to omali-
zumab [34, 35].
Studies evaluating the efficacy of up-dosing of omalizumab to 450 mg or 
600 mg in a month revealed a comparable benefit for CSU patients with partial or 
non-response to 300 mg of omalizumab [26, 27, 36]. There also reports that short-
ening the injection interval can lead to complete response inpatients with partial 
or no response to omalizumab 300 mg every 4 weeks. The most recent guidelines 
recommend cyclosporine add-on as a fourth-line treatment in CSU patients whose 
urticaria is not controlled with omalizumab treatment [3, 4, 37].
6. Omalizumab treatment for chronic inducible urticaria
As chronic inducible urticaria (CIndU), induced by common physical stimuli 
including exposure to cold or heat, skin friction or pressure, sunlight, and exercise, 
with longer duration, difficult to avoid the offending trigger, CIndU affects severely 
patients’ quality of life. A recent study reported that up to 76% of CSU patients 
were found to have a concurrent CIndU and these patients have more severe 
7
The Use of Omalizumab in Chronic Urticaria: Available Data and Future Aspects of Anti-IgE…
DOI: http://dx.doi.org/10.5772/intechopen.97226
urticaria [38]. While omalizumab has been used to successfully treat CSU on the 
basis of strong evidence from randomized controlled trials, real-life studies, and 
meta-analyses, omalizumab is not yet licensed for CIndU.
A meta-analysis reported recently that omalizumab has substantial benefits in 
patients with various CIndUs [16]. Variation of omalizumab use was seen between 
the CIndU subtypes, with the strongest evidence available in patients with 
symptomatic dermographism (complete or partial response in 38/54 patients), 
cold urticaria (complete/partial response in 41/51 patients), and solar urticaria 
(complete/partial response in 28/36 patients). Little or no evidence was available 
on vibratory, aquagenic and contact urticaria.
A randomized, placebo-controlled trial involving 55 patients with symptomatic 
dermographism revealed that significant improvement in critical friction thresholds 
after 10 weeks of treatment with omalizumab 150 mg and 300 mg, compared with 
the placebo group [39]. No significant difference in efficacy was observed between 
omalizumab 150 mg and 300 mg groups. After 10 weeks of treatment, 6 (33%) of 
18 receiving 150 mg of omalizumab and 8 (42%) of 19 patients receiving 300 mg 
of omalizumab did not respond at all compared with 15 (83%) of 18 in the placebo 
group. A retrospective observational study showed 86% of patients achieved a 
complete response [32].
Cold urticaria is the second most prevalent physical urticaria. A randomized, 
placebo-controlled trial including 31 patients with cold urticaria demonstrated 
significant clinical superiority of omalizumab versus placebo [40]. Mean changes 
in critical temperature threshold after 10 weeks of treatment were significantly 
higher in the omalizumab 150 mg and 300 mg groups compared with the placebo 
group. Improvements were seen by week 4. No significant dose-dependent response 
between the omalizumab 150 mg and 300 mg groups. After 10 weeks of treatment, 
10% of 10 patients receiving omalizumab 150 mg and 22% of 9 patietns receiving 
300 mg of omalizumab were non-responders compared with 75% of 12 patients in 
the placebo group.
Due to a longer symptomatic episode and a subtype of frequently accompanied 
in patients with CSU, delayed pressure urticaria was reported to result in a signifi-
cant impairment of quality of life than other types of CIndU [41]. Furthermore, it is 
difficult to control delayed pressure urticatia with up-dosing of antihistamine treat-
ment [16]. In a meta-analysis that found 11 publications of omalizumab treatment 
for patients with delayed pressure urticaria, favorable results were obtained [16]. 
Starting with 150 mg of omalizumab, 60% ~ 88% of patients with delayed pressure 
urticatia achieved complete control within 2 days.
There is sparse data on the efficacy of omalizumab for patients with cholinergic 
urticaria. Among retrospective analyses, one from the Germany [32] reported 62% 
of complete response and 25% of no response assessed by provocation test, whereas 
another study reported from Korean populations [42] showed relatively lower 
complete responders (4.8%, 1 of 21 patients).
Taken together, although evidence of the efficacy of omalizumab in CIndU has 
been accumulating, more data from randomized controlled trials are needed to 
establish the dose, injection interval, and treatment duration according to the type 
of CIndU. To date, while many studies proved a lower dose of 150 mg was enough to 
reach a good response, however as like in CSU patients, increasing dose of omali-
zumab in some patients with CIndU had better response. Most of studies found 
that CIndU patients achieved complete symptom control after the first injection 
of omalizumab, however, once discontinued, all patients got worse within 8 weeks 
after the last injection to need retreatment of omalizumab because antihistamines 
did not work for these patients [16].
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7. Omalizumab treatment for angioedema
In X-ACT (Xolair Effects on Angioedema in Chronic Spontaneous Urticaria 
Treatment) study, a phase III, randomized, double-blind study involving selectively 
CSU patients with angioedema and wheals, omalizumab was superior to placebo 
in improving CU-Q2oL scores and reduction in angioedema-burdened days by 
three times during the 28-week of treatment [14, 43]. Angioedema was a prevalent 
symptom in patients with CSU in the three pivotal phase 3 studies of omalizumab 
and occurred in 44–53% of patients at baseline [9–11]. Treatment with 300 mg of 
omalizumab was efficacious in reducing patient-reported angioedema in patients 
with CIU/CSU who were symptomatic despite a variety of treatments [44]. Urgert 
et al. evaluated systematically the efficacy of omalizumab in CSU patients accom-
panying angioedema using 5 studies [21]. They provided high quality evidence of 
that the proportion of angioedema-free days were higher in the omalizumab group 
compared with placebo as well as use of rescue medications from baseline was 
significantly reduced in the omalizumab 300 mg group.
8. Omalizumab treatment for special populations
Although ASTERIA II [10] and GLACIAL [11] did include patients with 12 years 
and older, none of these larger trials addressed the use of omalizumab in the 
pediatric population below this age. Although significantly less common in the 
pediatric population, CU affects 0.1% to 0.3% of children with a similar morbidity 
profile as the adult population. A case series of the use of omalizumab for CU in 
the 4 patients in age from 4 to 16 years found that all 4 patients obtained complete 
response to omalizumab 150 mg monthly for the younger ones (age 4 and 5 years) 
and 300 mg monthly for the older patients at 10 and 16 years without any reported 
adverse events [45].
The EXPECT study evaluated the use of omalizumab during pregnancy [46]. 
In total, 191 pregnant women were included who had moderate to severe asthma 
and received at least 1 dose of omalizumab 8 weeks before conception or at any 
time during pregnancy. Based on the known outcomes of 169 pregnancies, there 
was no significant difference in spontaneous abortion, major congenital anoma-
lies, prematurity, or low birth weight compared with a similar asthma population 
reported in previous studies [47, 48]. Because of the small number of patients 
in the study, it is difficult to draw any conclusions of safety on the use of omali-
zumab during pregnancy for CU [28]. Further studies are needed with larger 
sample sizes.
9. Safety issues of omalizumab
Safety was closely evaluated in all the randomized phase III trials [9–11]. 
ASTERIA II reported more headaches in the omalizumab 150 mg group compared 
with placebo but otherwise had no significant differences in adverse events. The 
GLACIAL study [11] showed no significant difference in adverse events between 
omalizumab group and placebo but did have some system-specific differences. In 
ASTERIA I, [9] headaches, arthralgia, and injection-site reactions were more com-
mon in the omalizumab groups but there was no significant difference in serious 
adverse events. No deaths, malignancies, or anaphylactic episodes were reported in 
these trials due to omalizumab.
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Overall, omalizumab is very well tolerated and adverse reactions occurred in 
patients taking omalizumab were compatible with those on placebo in prospective, 
randomized trials for CU [3, 20, 49–51]. The most seriously considered adverse 
reaction is anaphylaxis-related to omalizumab that is defined as a combination of 
angioedema of the throat or tongue, bronchospasm, hypotension, syncope, and/or 
urticaria [52]. Omalizumab joint task force reviewed clinical trials and postmarket-
ing surveillance data on omalizumab-induced anaphylaxis or anaphylactoid reac-
tions [53]. They found a total of 35 patients with 42 episodes of anaphylaxis-related 
to omalizumab injection. Considering a total of 39510 patients who had exposed 
once to omalizumab, they estimated an anaphylaxis-reporting rate of 0.09% of 
patients [53]. The risk of anaphylaxis in patients with CU appears to be less than in 
those treated for asthma. In addition, there does not seem to be a dose-related effect 
on adverse events.
10. Anti-IgE therapeutics under development
10.1 Ligelizumab
Ligelizumab (QGE031) is a new promising humanizaed monoclonal anti-IgE 
antibody under development for the treatment of CSU patients. It has a 40-fold to 
50-fold greater affinity to IgE compared with omalizumab [54]. In a phase 2b multi-
center randomized placebo controlled trial, patients with antihistamine-refractory 
CSU were randomized to placebo, 300 mg of omalizumab, or 24, 72, or 240 mg 
of ligelizumab administered by subcutaneous injection with 4-week interval for 
20 weeks [55]. Ligelizumab demonstrated rapid onset of action, dose-dependent 
efficacy, and superiority to omalizumab. At 12 week, a total of 30%, 51%, and 42% 
of the patients treated with 24 mg, 72 mg, and 240 mg of ligelizumab, respectivity, 
had complete control of urticaria, as compared with 26% of the patients receiving 
omalizumab 300 mg and none in the placebo group. More than 50% of patients 
taking 240 mg of ligelizumab were complete responders, a response rate twice than 
that seen in the omalizumab group. Furthermore, the mean time to relapse after 
the last injection was 4 weeks for omalizumab vs. 10 weeks for ligelizumab. Except 
higher rates of mild injection site reactions in the 240 mg of ligelizumab group, no 
difference in safety profiles of placebo, omalizumab, and ligelizumab was observed. 
The most frequently reported adverse events were viral upper respiratory tract 
infection and headache. No deaths or anaphylaxis events were reported in any of the 
trial groups. On the basis of favorable response of ligelizumab with a rapid onset of 
action, improved and sustained efficacy in antihistamine-refractory CSU patients 
over 300 mg of omalizumab treatment, now two phase III, multi-center, random-
ized, double-blind, active- and placebo-controlled, parallel-group studies (PEARL 
1 and 2) are running. The primary outcome of these two trials will measure absolute 
change from baseline in UAS7 at Week 12 [56].
10.2 Quilizumab
Quilizumab, a humanized, afucosylated, monoclonal IgG1 antibody, binds 
membrane IgE at the M1-prime segment, which is absent in soluble IgE. In animal 
studies, quilizumab bound membrane IgE on IgE-switched B cells and plasmablasts 
and depleted them through apoptosis and antibody-dependent cell-mediated 
cytotoxicity [57]. In clinical trials, quilizumab reduced serum total and specific IgE 
levels in healthy volunteers and in patients with allergic rhinitis or mild asthma [58]. 
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However, because quilizumab did not provide a significant differences in the clinical 
endpoints compared with placebo, it was indicated that ongoing IgE switching and 
stimulation of B-cell memory may not be key disease drivers [59].
11. Conclusion
Therapeutics modulating IgE levels and activities provide an efficient and very 
tolerable add-on treatment for patients with antihistamine-refractory CU. With 
a strong evidence of the efficacy and safety, omalizumab is recommended as the 
first choice of treatment for CSU patients who still suffered from urticaria with 
up-dosing antihistamine treatment in recent international guidelines. However, as 
it is not disease-modifying agent, there is a subpopulation of CSU patients respond-
ing incompletely or never to omalizumab. Moreover, clinical evidence on chronic 
inducible urticaria (CIndU) and special populations, such as children and older 
patients is still not enough. Thus, a new anti-IgE treatment, ligelizumab is actively 
evaluated in the efficacy compared with both placebo and omalizumab. Further 
understandings on the pathogenesis of CU can lead to the development of new 
mechanism-based therapeutics for CU patients.
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